Common medications can significantly alter brain scan results for people with Parkinson’s

A new study published in the European Journal of Nuclear Medicine and Molecular Imaging reveals that several everyday prescription drugs can alter the results of specialised brain scans used in Parkinson’s. The researchers found that certain medications can make dopamine levels in the brain appear lower on a scan than they genuinely are. Doctors and specialists frequently use a type of brain imaging known as a dopamine transporter scan to assess the health of dopamine producing nerve cells. The scan works by sending a small, safe imaging marker into the bloodstream, which attaches itself to dopamine transporters in an area of the brain called the striatum. By measuring where this marker settles, clinicians can see a visual map of dopamine activity. However, if other medicines latch onto those exact same docking stations, the scan marker cannot bind properly, creating an optical illusion that nerve cell loss is more severe than it truly is. To measure the real world impact of this effect, the research team examined medical records and imaging data from 752 people with Parkinson’s participating in the international Parkinson’s Progression Markers Initiative. Within this group, 188 people were taking medications suspected of interacting with dopamine transporters, while 564 people were not taking any of these treatments. The scientists specifically looked at five widely used medications: methylphenidate, modafinil, bupropion, venlafaxine, and codeine. The results showed that medication use had a notable influence on brain scans across the board. People taking the interacting drugs had significantly lower scan binding in key brain regions, including the caudate nucleus and the putamen. When looking closely at specific medicines, the differences were striking. The largest reductions occurred with methylphenidate, a stimulant often prescribed for attention or daytime sleepiness, and modafinil, an alertness drug used for severe fatigue. In people taking methylphenidate, scan signals in parts of the striatum dropped by up to 33 percent. For those taking modafinil, the signal fell by roughly 25 percent. Antidepressant medications such as bupropion and venlafaxine also caused measurable drops in scan signal, although their impact was considerably smaller. In contrast, codeine showed no meaningful interference with the scans. These findings carry important practical implications for everyday clinical care. If a healthcare team is unaware that someone is taking a drug like modafinil or methylphenidate, they could misread a brain scan as showing advanced dopamine loss rather than simple drug competition. The study authors suggest that clinicians should always review a person’s complete medication list before scheduling brain imaging. In select situations where it is safe to do so, temporarily pausing an interfering prescription for a short window prior to the appointment may help ensure that scan readings remain clear, accurate, and truly representative.